Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SYNAPSE-MG: NMD670 in Myasthenia Gravis
NCT06414954Phase 2Recruiting
- Sponsor
- NMD Pharma
- Start
- May 2024
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 10
01
Overview
Phase 2, randomised, double-blind trial of ignaseclant in myasthenia gravis (MG) (4 arms), sponsored by NMD Pharma. Primary endpoint: Quantitative Myasthenia Gravis at 21 days. Started May 2024; status: recruiting.
02
Drugs
ignaseclant
03
Conditions
myasthenia gravis (MG)
Beyond the preview
Go deeper on NCT06414954.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06414954.